What are the new guidelines for assessing and treating diabetic ketoacidosis (DKA) using beta hydroxybutyrate (BHB) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Beta-Hydroxybutyrate in DKA Assessment: Updated Guidelines

Direct Blood β-Hydroxybutyrate is Now the Preferred Diagnostic and Monitoring Test

Blood β-hydroxybutyrate (β-OHB) measurement has replaced traditional urine ketone testing as the gold standard for both diagnosing and monitoring DKA resolution, and should be measured every 2-4 hours during active treatment. 1, 2


Why β-Hydroxybutyrate Matters

  • β-OHB is the predominant and strongest ketoacid in DKA, comprising the majority of ketone bodies during ketoacidosis, making it the most clinically relevant marker. 1, 2

  • Traditional nitroprusside-based urine dipsticks and serum ketone tests are fundamentally flawed because they only detect acetoacetate and acetone—they completely miss β-hydroxybutyrate. 1, 2

  • During DKA treatment, β-OHB converts to acetoacetate, which paradoxically makes nitroprusside tests appear worse even as the patient clinically improves—this can mislead clinicians into thinking treatment is failing. 1, 2


Diagnostic Thresholds

  • For classic DKA diagnosis: β-OHB ≥3.8 mmol/L in adults, combined with glucose >250 mg/dL, pH <7.3, and bicarbonate <15 mEq/L. 2

  • For euglycemic DKA (EDKA): β-OHB elevation with glucose <250 mg/dL, pH <7.3, bicarbonate <15-18 mEq/L, and anion gap >10-12 mEq/L—particularly important in patients on SGLT-2 inhibitors. 3

  • Normal β-OHB levels: <0.5 mmol/L; any elevation suggests ketosis or impending DKA. 1, 2


Monitoring Protocol During Treatment

Initial Assessment

  • Obtain β-OHB immediately as part of the initial diagnostic workup alongside glucose, venous blood gas, electrolytes, BUN, creatinine, and anion gap. 1

During Active Treatment

  • Measure β-OHB every 2-4 hours during the treatment phase, checking simultaneously with glucose, electrolytes, and venous pH. 1

  • This frequency allows real-time tracking of ketosis resolution, which consistently takes longer than hyperglycemia to clear—a critical point that prevents premature insulin discontinuation. 1, 2

  • β-OHB correlates strongly with pH (r = -0.56 to -0.83) and bicarbonate (r = -0.24), making it a reliable marker of acidosis severity. 4, 5

Resolution Criteria

  • DKA is resolved when ALL of the following are met: glucose <200 mg/dL, venous pH >7.3, serum bicarbonate ≥18 mEq/L, anion gap ≤12 mEq/L, and β-OHB normalizes (<0.5 mmol/L). 3, 1

  • β-OHB normalizes 3-5 hours earlier than urine ketones, allowing for more accurate timing of treatment transitions. 4


Critical Pitfalls to Avoid

Never Use Nitroprusside Tests for Monitoring

  • The American Diabetes Association explicitly recommends against using nitroprusside-based ketone tests (urine or serum) to monitor DKA treatment response. 1, 2

  • These tests will show falsely worsening results as β-OHB converts to acetoacetate during successful treatment, potentially leading to inappropriate treatment intensification. 1, 2

Don't Stop Insulin When Glucose Normalizes

  • Continue insulin infusion until β-OHB normalizes, not just until glucose falls below 200 mg/dL. 1, 2

  • Add dextrose 5% to IV fluids when glucose drops below 250 mg/dL to prevent hypoglycemia while continuing insulin to clear ketones. 3, 1

Urine Ketones Can Persist After Resolution

  • 10% of patients still have positive urine ketones when blood β-OHB has already normalized—relying on urine ketones leads to unnecessary prolongation of IV insulin. 4

Special Populations Requiring β-OHB Monitoring

  • Patients on SGLT-2 inhibitors are at high risk for euglycemic DKA and should have β-OHB checked with any unexplained symptoms, even with glucose <250 mg/dL. 3, 2

  • Type 1 diabetes patients with intercurrent illness should check β-OHB at home when glucose >250 mg/dL or with symptoms of ketosis (nausea, abdominal pain, vomiting). 2

  • Pregnant patients can have false-positive urine ketones in up to 30% of cases due to starvation ketosis, making blood β-OHB essential for accurate diagnosis. 2


Practical Implementation Algorithm

  1. At presentation: Obtain blood β-OHB immediately alongside initial labs. 1

  2. If β-OHB ≥3.8 mmol/L with acidosis: Diagnose DKA and initiate treatment protocol. 2

  3. During treatment: Recheck β-OHB every 2-4 hours with glucose and electrolytes. 1

  4. When glucose <250 mg/dL: Add dextrose to fluids but continue insulin infusion. 3, 1

  5. When β-OHB <0.5 mmol/L AND pH >7.3 AND bicarbonate ≥18 mEq/L: DKA is resolved; transition to subcutaneous insulin. 3, 1

  6. Give basal insulin 2-4 hours before stopping IV insulin to prevent rebound ketoacidosis. 3, 1

References

Guideline

Diagnostic Criteria and Management of Diabetic Ketoacidosis (DKA)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Diabetic Ketoacidosis Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnosis and Management of Euglycemic Diabetic Ketoacidosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Capillary beta-hydroxybutyrate determination for monitoring diabetic ketoacidosis].

Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.